A system for injecting includes a syringe body having proximal and distal ends, a syringe interior, and a syringe flange at the proximal end thereof. The system also includes a stopper member disposed in the syringe interior. The system further includes a plunger member coupled to the stopper member. The plunger member includes a rotatable member configured to insert the stopper member distally in the syringe interior relative to the syringe body with rotation of the rotatable member. The plunger member further includes a proximal portion proximal of the rotatable member configured to be moved distally to also insert the stopper member distally in the syringe interior relative to the syringe body to eject about microliters of fluid from the syringe interior.

Antigens of Toxoplasma gondii that provide specific and strong delayed type hypersensitivity (DTH) immune response, or which stimulate IFN-γ secretion, are used for testing subjects for infection. Any skin testing format may be adapted for testing for the delayed type hypersensitivity, including a patch, a needle, or a prong. Presence of DTH indicates infection. Alternate methods of detecting a T cell response including monitoring IFN-γ secretion may be used.

This disclosure includes syringes, kits containing the same, and related methods. Some syringes are pre-loaded with paste and have a syringe body defining a reservoir having an internal first transverse dimension, a paste disposed within the reservoir, the paste having a solids concentration of greater than 50 mg/mL, a needle defining a lumen having an internal second transverse dimension that is smaller than the first transverse dimension, the needle configured to be in fluid communication with the reservoir to allow intracutaneous delivery of the paste, and a plunger and/or piston disposed within the reservoir and configured to be moved to dispense paste from the reservoir through the lumen. Some syringes include a fitting (e.g. Luer fitting) disposed on the syringe body and in fluid communication with the reservoir and a sealing cap disposed on the Luer fitting to seal the reservoir.

A system for injecting includes a syringe body, a syringe interior, a syringe flange, and a stopper member and an injectable fluid disposed in the syringe interior. The system also includes a plunger member coupled to the stopper member. The system further includes a finger flange removably coupled to the syringe flange, the finger flange defining a pair of side openings and a pair of bumps adjacent respective side openings. Moreover, the system also includes a swing spacer rotatably coupled to the finger flange, the swing spacer defining a pair of arms, a pair of pivot pins, two pairs of slots, and a pair of indentations. The swing spacer is configured to define a distance of movement of the plunger member relative to the syringe body along a longitudinal axis of the syringe body, thereby defining a dose of the injectable fluid.

A wearable drug delivery device that can deliver a liquid drug stored in a container to a patient is provided. The container can be a prefilled cartridge that can be loaded into the drug delivery device by the patient or that can be preloaded within the drug delivery device when provided to the patient. A sealed end of the container is pierced to couple the stored liquid drug to a needle conduit that is coupled to a needle insertion component that provides access to the patient. A drive system of the drug delivery device can expel the liquid drug from the cartridge to the patient through the needle conduit. The drive system can be controlled to provide the liquid drug to the patient in a single dose or over multiple doses.

Antigens of Toxoplasma gondii that provide specific and strong delayed type hypersensitivity (DTH) immune response, or which stimulate IFN-y secretion, are used for testing subjects for infection. Any skin testing format may be adapted for testing for the delayed type hypersensitivity, including a patch, a needle, or a prong. Presence of DTH indicates infection. Alternate methods of detecting a T cell response including monitoring IFN-y secretion may be used.

A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

A syringe for withdrawing an aspirate from a body for micro fat grafting is provided. The syringe includes a barrel having an inner wall extending therein. The inner wall has one or more apertures formed therein allowing the aspirate to contact an absorbent positioned between the inner wall and an outer wall of the barrel. A plunger moves longitudinally within the barrel along the inner wall and has a gasket attached to a proximal end forming a seal against the inner wall. The absorbent may take many forms to absorb a non-fat cell portion of the aspirate. A related method includes retracting the plunger from a first position to draw the aspirate from a harvest site of a body into the barrel, exposing the aspirate to the absorbent, and moving the plunger toward the first position so a remaining portion of the aspirate is no longer exposed to the absorbent.

A dosing system for transferring an aseptic fluid in dosages into a container, comprising a peristaltic pump configured such that the filling accuracy for fill volumes of the aseptic fluid <100 μL is ±3 μL.

Precision low-dose, low-waste syringe configurations have a reduced diameter lumen for dispensing 0.01 ml increments of contents. Plunger and lumen configurations and a needle interface eliminate dead space. Ergonomic attachments improve the control and precision of delivery of syringes. An attachment main body includes a gripping surface to permit a user to engage the attachment and move the attachment main body, and thus the syringe plunger relative to the syringe barrel using sliding movement. Optical enhancement features are provided on the attachment to improve the readability of gradations and plunger position. The attachment may be provided with an assist feature, which may be a traction wheel mounted on the attachment body. An alternative configuration suitable for syringe contents of higher viscosity may include a pair of toothed pinion gears on a wheel and which cooperate with respective toothed racks formed on or fastened to the syringe body.